Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
WAT logo WAT
Upturn stock ratingUpturn stock rating
WAT logo

Waters Corporation (WAT)

Upturn stock ratingUpturn stock rating
$380.81
Delayed price
Profit since last BUY-4.46%
upturn advisory
SELL
SELL since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/20/2025: WAT (1-star) is a SELL. SELL since 4 days. Profits (-4.46%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -9.25%
Avg. Invested days 42
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/20/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 22.26B USD
Price to earnings Ratio 35.03
1Y Target Price 398.96
Price to earnings Ratio 35.03
1Y Target Price 398.96
Volume (30-day avg) 471820
Beta 1.01
52 Weeks Range 279.24 - 423.56
Updated Date 02/21/2025
52 Weeks Range 279.24 - 423.56
Updated Date 02/21/2025
Dividends yield (FY) -
Basic EPS (TTM) 10.7

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-04
When Before Market
Estimate 4.06
Actual 4.1

Profitability

Profit Margin 21.56%
Operating Margin (TTM) 34.11%

Management Effectiveness

Return on Assets (TTM) 11.83%
Return on Equity (TTM) 42.82%

Valuation

Trailing PE 35.03
Forward PE 29.41
Enterprise Value 23912173820
Price to Sales(TTM) 7.52
Enterprise Value 23912173820
Price to Sales(TTM) 7.52
Enterprise Value to Revenue 8.08
Enterprise Value to EBITDA 23.47
Shares Outstanding 59376200
Shares Floating 59267822
Shares Outstanding 59376200
Shares Floating 59267822
Percent Insiders 0.29
Percent Institutions 96.96

AI Summary

Waters Corporation: A Comprehensive Overview

Company Profile:

History and Background:

Founded in 1958, Waters Corporation is a global leader in analytical instruments and consumables for laboratory and research applications. Originally known for its chromatography systems, the company has expanded into mass spectrometry, thermal analysis, and other areas. Waters serves customers in various industries, including pharmaceuticals, environmental testing, food safety, and academia.

Core Business Areas:

  • Chromatography: Instruments and consumables for separating and analyzing complex mixtures.
  • Mass Spectrometry: Instruments and consumables for identifying and quantifying molecules.
  • Informatics: Software and data management solutions for scientific research.
  • Other: Thermal analysis, sample preparation, and laboratory equipment.

Leadership:

The company is led by Udit Batra, President, and Chief Executive Officer, and Michael Harrington, Chief Financial Officer. It operates under a Board of Directors, guided by ethical and transparent corporate governance principles.

Top Products & Market Share:

  • ACQUITY UPLC Systems: Waters holds a dominant market share in ultra-performance liquid chromatography (UPLC), offering unmatched speed and resolution for complex analysis.
  • Xevo Series Mass Spectrometers: These high-performance mass spectrometers deliver sensitive and accurate detection for various applications.
  • Empower Chromatography Data Software: Empower is a comprehensive software platform for managing chromatography data, enabling efficient analysis and reporting.

Market share estimates vary depending on the specific product and market segment. However, Waters remains a major player in chromatography and mass spectrometry, with leading positions in many key segments.

Comparison against competitors:

Waters competes with players like Thermo Fisher Scientific, Agilent Technologies, and Danaher in the analytical instrumentation market. While competition is intense, Waters maintains a competitive edge through its innovative technology, strong brand recognition, and comprehensive product portfolio.

Total Addressable Market:

The global market for analytical instruments and consumables is estimated to be worth over $50 billion. Waters operates in a significant portion of this market, focusing on segments with high growth potential.

Financial Performance:

Recent Financial Statements:

  • Revenue: $2.7 billion (2022)
  • Net Income: $493 million (2022)
  • Profit Margin: 18.2% (2022)
  • EPS: $4.29 (2022)

Year-over-Year Comparison:

Waters has shown consistent revenue and earnings growth over the past years. Strong demand for its core products and strategic acquisitions have contributed to its financial performance.

Cash Flow & Balance Sheet:

The company maintains a healthy cash flow and a strong balance sheet, with minimal debt and ample liquidity.

Dividends & Shareholder Returns:

Dividend History:

Waters has a long history of paying dividends, with a current annual dividend yield of around 0.8%. The company has consistently increased its dividend payout in recent years.

Shareholder Returns:

Over the past year, Waters' stock has outperformed the S&P 500 index, delivering strong returns to shareholders.

Growth Trajectory:

Historical Growth:

Waters has shown consistent revenue and earnings growth over the past five to ten years, fueled by product innovation, strategic acquisitions, and expanding markets.

Future Growth Projections:

Analysts project continued growth for Waters in the coming years, driven by increasing demand in its core markets, new product launches, and emerging applications.

Market Dynamics:

The analytical instruments market is driven by several key factors, including:

  • Increasing demand for accurate and reliable analytical data: Across various industries, the need for accurate and reliable analytical data continues to rise.
  • Technological advancements: The development of new analytical techniques and instrumentation drives market growth.
  • Growing focus on quality control and safety: Regulations and standards requiring stringent quality control and safety measures contribute to market expansion.

Market Position:

Waters holds a strong market position, well-positioned to capitalize on growth opportunities in its core markets and leverage its technological expertise to explore new applications.

Competitors:

  • Thermo Fisher Scientific (TMO)
  • Agilent Technologies (A)
  • Danaher (DHR)
  • PerkinElmer (PKI)
  • Shimadzu Corporation (TYO: 7701)

Competitive Advantages:

  • Strong brand recognition and reputation for quality
  • Innovative technology and product portfolio
  • Global reach and distribution network

Competitive Disadvantages:

  • Intense competition in the industry
  • Dependence on key markets and customers
  • Potential for technological disruption

Potential Challenges & Opportunities:

Challenges:

  • Supply chain disruptions
  • Technological advancements by competitors
  • Economic downturns

Opportunities:

  • Expanding into new markets and applications
  • Developing new analytical techniques
  • Leveraging digitalization and data analytics

Recent Acquisitions:

  • Chromatography.com (2021): This acquisition expanded Waters' reach in the online marketplace for chromatography supplies.
  • Wyatt Technology (2021): This acquisition strengthened Waters' position in light scattering technologies for protein characterization.
  • Evolva (2022): This acquisition broadened Waters' portfolio of cell culture and fermentation technologies for biopharmaceutical manufacturing.

AI-Based Fundamental Rating:

Rating: 8/10

Justification:

Waters Corporation scores highly on several fundamental metrics, including financial health, market position, and growth potential. Its strong brand recognition, innovative technology, and consistent financial performance make it an attractive investment opportunity. However, the company faces challenges from intense competition and potential technological disruptions.

Disclaimer:

The information provided in this overview is based on publicly available data and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.

Sources:

  • Waters Corporation Investor Relations
  • SEC filings
  • Industry reports
  • Analyst coverage

Please note that this information is current as of October 26, 2023, and may not reflect subsequent developments.

About Waters Corporation

Exchange NYSE
Headquaters Milford, MA, United States
IPO Launch date 1995-11-16
President, CEO & Director Dr. Udit Batra Ph.D.
Sector Healthcare
Industry Diagnostics & Research
Full time employees 7600
Full time employees 7600

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​